- Home
- Equipment
- usa massachusetts
- oncology
Show results for
Refine by
Oncology Equipment Supplied In Usa Massachusetts
45 equipment items found
Manufactured by:AVEO Pharmaceuticals, Inc. based inBoston, MASSACHUSETTS (USA)
AV-353 is the Company’s potent, selective, high affinity inhibitory antibody specific to Notch 3. The Notch 3 signaling pathway is important in cell-to-cell communication involving gene regulation mechanisms that control multiple cell differentiation processes during the entire life cycle. Scientific literature has implicated the Notch 3 receptor pathway in multiple diseases, including ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-342 is a bispecific antibody comprised of an anti-GPC3 antagonistic antibody linked to a 4-1BB (CD137) agonistic anticalin ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS172738 is a highly selective, reversible, ATP-competitive RET (Rearranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas. ...
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Prostate cancer is the most prevalent cancer among men, and it is the second leading cause of cancer death among men in the United States. More than 500,000 cases are diagnosed annually. In the U.S. this year, 1 in 6 males will develop the disease and 30,000 others will die of it. Although prostate cancer mostly affects elderly men, the number of younger men with prostatic carcinoma is ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
APH-0912 is a combination of a Taxotere® prodrug and monoclonal antibody targeted to treat metastatic cancer. The prodrug is a combination of a docetaxel molecule, the potent anticancer drug, and a sugar molecule to enhance solubility covalently linked to a tumor-specific antibody. This molecular combination is not bioactive prior to administration. After infusion and adsorption onto targeted ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Poor Solubility and Associated Formulation and Bioavailability Difficulties. Although paclitaxel is an effective anticancer drug, its solubility is low (~ 0.4 µg/mL), which limits its medical utility to intravenous applications. Docetaxel (Taxotere®) was developed as a paclitaxel derivative having improved water solubility; its solubility, however, is only ~ 14 µg/mL. Several ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Despite the widespread use of the 5-HT3 receptor antagonist anti-emetics such as Palonosetron (Aloxi; Eisai), Ondansetron (Zofran®; GSK), Granisetron (Kytril®; Roche Pharmaceuticals), and Dolasetron (Anzemet®; Aventis), CINV continues to be reported by up to 70% of adult patients receiving highly emetogenic chemotherapy agents and 58% of school-age and adolescent-age children ...
Manufactured by:Stilla Technologies based inVillejuif, FRANCE
Get ready-to-use, fully-validated panels for the detection and quantification of nucleic acids. Crystal Digital PCR™ kits allows researchers to detect and quantify nucleic acids with ready-to-use, pre-designed assays for fully-validated target panels. These digital PCR panel kits are specially developed by Stilla Technologies and its partners ID Solutions. For fully-customizable kits and/or ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology - Multiple ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Multiple ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Multiple ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology; Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Sana Biotechnology based inSeattle, WASHINGTON (USA)
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...
Manufactured by:Quanterix Corporation based inBillerica, MASSACHUSETTS (USA)
The Quanterix SP-X Imaging and Analysis System is a complete benchtop system that offers true multiplex detection at both acute and baseline levels. For the first time, oncology and immuno-oncology researchers and others who rely on multiplexing capabilities have an easy-to-use platform to help optimize workflows, speed up their research and ultimately ...
Manufactured by:Gentuity, LLC based inSudbury, MASSACHUSETTS (USA)
It's important to note that the usage of this product must be performed by healthcare professionals trained in radiation oncology due to the complex nature of its application and the associated potential risks and adverse events. The technology highlights an intersection of nuclear medicine and oncology, providing a valuable tool in the management of hepatic ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE800 is an orally administered rationally-defined bacterial consortium immuno-oncology candidate. VE800 consists of 11 clonal human commensal bacteria strains manufactured under cGMP conditions and selected for their ability to induce CD8+ T cells, potentiate the immune system’s attack of tumors and enhance the effects of checkpoint ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of these cancer immunotherapies. YSOPIA is exploring the role of specific keystone bacteria with high therapeutic potential in the oncology field based on a strong understanding of their mechanisms of ...